Sanofi Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (73)

Latest Posts

About This Stock More About This Stock
Warren Buffet Is Buying These 3 Stocks Right Now
Article By: TipRanks
Sunday, February 18, 2018 8:45 AM EST
Finding fresh investing inspiration can be a challenge, but if you examine billionaire Warren Buffett’s moves, you can find insights from one of the world’s most successful fund managers. Here are 3 stocks Buffett is buying and 3 he is selling...
In this article: BK, GM, IBM, SNY, AAPL, TEVA
Read
E Sh-tdown To End
Article By: Vivian Lewis
Monday, January 22, 2018 12:15 PM EST
News today from Bermuda, Brazil, Britain, Canada, Chile, China, Colombia, Denmark, Dutch Antilles, France, Finland, Germany, India, Ireland, Israel, Italy, Japan, Mexico, Panama, Sweden, Switzerland, and the USA where the sh-tdown is being ended.
In this article: AIG, CEA, SLFPY, NTR, BLX, BP, EONGY, SLB, EC, DGRLY, AGU, CB, CZZ, SQM, VR, XYL, PPEHF, SNY, TEVA, NVO, SHPG, MZOR, SANM, NOK, TCEHY, SAN, TCTZF, DCM, MXE, CTY Also: AMZN
Read
Sanofi Acquires Bioverativ For $105 Per Share In Cash, Or $11.6B
Article By: The Fly
Monday, January 22, 2018 7:42 AM EST
Sanofi and Bioverativ have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ for $105 per share in cash, representing an equity value of approximately $11.6B.
In this article: BIVV, SNY
Read
Sanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes Weak
Article By: Zacks Investment Research
Thursday, November 2, 2017 11:52 AM EST
Sanofi reported third-quarter 2017 earnings of $1.00 per American depositary share, which were in line with the Zacks Consensus Estimate. Earnings declined 4.5% on a reported basis.
In this article: SNY Also: MRK, REGN, AMGN
Read
Week In Review: Another Billion Dollar Week For China Life Science Deals
Article By: ChinaBio® Today
Saturday, September 30, 2017 5:55 PM EST
Shanghai Pharma Holding (SHA: 601607) may acquire part of Alvogen -- possibly Alvogen's US operations -- according to Bloomberg. Alvogen is a US-based generic drug maker thought to be worth as much as $4 billion.
In this article: NVO, SNY, SVA, AMGN, GILD, ZLAB, TSRO
Read

PARTNER HEADLINES

Latest Tweets for $SNY

No tweets yet!